Head to Head Review: Polarean Imaging (OTCMKTS:PLLWF) vs. MaxCyte (NASDAQ:MXCT)

Polarean Imaging (OTCMKTS:PLLWF) and MaxCyte (NASDAQ:MXCT) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, analyst recommendations, earnings, institutional ownership, valuation, profitability and risk.

Profitability

This table compares Polarean Imaging and MaxCyte’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Polarean Imaging	N/A	N/A	N/A
MaxCyte	-77.97%	-15.52%	-13.57%

Institutional and Insider Ownership

68.8% of MaxCyte shares are held by institutional investors. 3.0% of MaxCyte shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Earnings and Valuation

This table compares Polarean Imaging and MaxCyte”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Polarean Imaging	N/A	N/A	N/A	N/A	N/A
MaxCyte	$45.44 million	8.70	-$37.92 million	($0.35)	-10.77

Polarean Imaging has higher earnings, but lower revenue than MaxCyte.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Polarean Imaging and MaxCyte, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Polarean Imaging	0	0	0	0	N/A
MaxCyte	0	0	4	0	3.00

MaxCyte has a consensus target price of $8.67, indicating a potential upside of 129.89%. Given MaxCyte’s higher probable upside, analysts clearly believe MaxCyte is more favorable than Polarean Imaging.

Summary

MaxCyte beats Polarean Imaging on 5 of the 8 factors compared between the two stocks.

About Polarean Imaging

Polarean Imaging plc operates as a drug-device manufacturer and service provider for noble gas polarizer devices in Canada, the United Kingdom, and the United States. The company engages in the research, development, and commercialization of novel imaging solutions with a non-invasive and radiation-free functional imaging platform. It also offers XENOVIEW, a hyperpolarized contrast agent indicated for use with magnetic resonance imaging (MRI) for evaluation of lung ventilation in adults and pediatric patients aged 12 years and older; and measurement station, chest coil, and dose delivery inhalation bags. Polarean Imaging plc was incorporated in 2016 and is based in Durham, North Carolina.

About MaxCyte

MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. The company also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. It licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. MaxCyte, Inc. was incorporated in 1998 and is headquartered in Rockville, Maryland.